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Debate: There are many existing IGRT options for highly 
accurate dose delivery. Is there a need for large-scale in-
room MR-guidance?  
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The statements that will be made highlighting the strong 
position we are already in when using all currently available 
advanced image-guidance strategies are used are the 
following:  
- If there is a necessity for on line MR-guidance, there is a 
general necessity for broad use of advanced image guidance 
strategies, particularly as successful screening programs such 
as those for lung cancer and potentially even pancreatic 
cancer are established, as this potentially leads to more 
localized disease being treated.  
- Several such strategies are now available but are 
underutilized, typically for lack of funding or perceived 
complexity. Recent developments such as FFF-delivery and 
fast collimators have, however, shortened a lot of treatments 
and thus rendered advanced imaging strategies more 
feasible. Considerable expertise is needed, as it is mandatory 
also for MR-guidance. 
- MR-guidance can be and has already been more easily 
applied to brachytherapy, a highly effective form of local 
therapy where technically applicable.  
- Continuous 2D-tracking based on fiducials placed in 
minimally invasive procedures has entered the clinical 
routine for the ablation of small lesions without complex 
interference of OARs.  
- 3D-imaging with CBCT, particularly in conjunction with 
breathhold strategies, still has considerable potential. 
Accuracies in the range of 3mm can be consistently achieved 
across treatment targets, in deep inspiration breathhold 
typically with very favorable dose distributions and 
straightforward dose accumulation. 4D-approaches are 
available, ultrafast "snapshot" volume imaging is ready to be 
deployed clinically. 
- Ultrasound, where applicable, allows not only for 
positioning but for tracking in 2D and 3D.  
- Surface scanning may simultaneously provide patient 
surveillance and gating signals during a therapy session.  
- Noncoplanar treatment strategies and high-LET radiation 
may have further potential to improve clinical results 
independent of imaging strategy and are currently not 
possible in conjunction with in-room MR-guidance. 
The statements suggesting that in-room MRI guidance will 
add significantly to the current armamentarium comprise 
the following: 
- Cancer is primarily a soft tissue disease. MRI offers 
unparalleled soft tissue contrast imaging across a wide range 
of cancer types and locations. In-room MRI guidance for 
cancer radiotherapy combines exquisite soft tissue imaging of 
the cancer and surrounding healthy structures with precision 
radiotherapy to optimally target the cancer and spare 
healthy tissues, affecting quality of life, cancer outcomes 
and reducing the health and economic burden of managing 
treatment-related side effects. 
- This ability to simultaneously image and target the cancer 
with radiotherapy is intuitive to patients and the treatment 
team alike. Indeed, the image quality of MRI-guidance is so 
high that a commercial online adaptive radiotherapy solution 
is only available with these systems.  
- Cancer physiology is heterogeneous and changes with time. 
MRI is the only in-room physiological targeting system for 
cancer radiotherapy. An example, tumor hypoxia, is a strong 
negative prognostic indicator of survival across a wide range 
of cancer sites, and the tumor hypoxic status changes over 
the time period of a single treatment. The ability to 
selectively image and target the most aggressive and 
resistant parts of the cancer opens up a new window to 
dramatically change cancer outcomes.  
- In addition to in-room MRI-guidance offering an improved 
treatment across a range of cancer sites, this new device also 
opens up the opportunity to explore the treatment of non-
oncologic diseases. An example is atrial fibrillation, a disease 
suffered by 6 million Europeans, with many of these patients 
treated in an invasive, long, expensive procedure. MRI-guided 
radiotherapy offers a non-invasive, short and cost-effective 
treatment of atrial fibrillation. This treatment is enabled by 
using MRI to solve the challenging problem of imaging and 
targeting small volumes affected by both respiratory and 
cardiac motion, a problem too difficult for other in-room 
imaging systems.  
- The improved outcomes and applications observed from in-
room MRI-guided radiotherapy will affect patient referral 
patterns and policy guidelines to increase the global 
radiotherapy need, benefiting the radiation oncology and 
global communities.  
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Advances in radiotherapy delivery have been due to improved 
technique and image guidance. In contrary to the "one size 
fits it all" paradigm, personalized medicine trys to 
incorporate all available imaging information in order to 
optimally delineate the target volume. It will be highlighted, 
in how far molecular imaging such as PET has become a 
cornerstone for certain types of cancer and how PET 
information may be integrated into target delineation. 
Furthermore, it will be discussed in how far there is a role for 
a biological target volume (BTV) and how appropriate 
margins can be chosen; new tracers beyond FDG are 
discussed. The meaning of MRI and its applications as well as 
available pitfalls will be presented employing an example of 
a brain tumor treatment. 
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Significant patient anatomy changes may occur during the 
course of radiotherapy, more particularly for head and neck, 
pelvic and lung tumours. These modifications may degrade 
the plan quality over time, and hence require treatment 
adaptation based on the anatomy depicted from images of 
the treatment day.  
Any comprehensive adaptive solution will necessarily require 
automatic tools that, first, depict patients who actually need 
adaptation (dose recomputation on daily image and clinical 
indicators of plan quality), and then assist the radiation 
oncologist/therapist in the labour-intensive task of target 
volumes and organs at risk recontouring. Ultimately, this 
approach should allow treatment plan re-optimization if 
required, without unmanageable additional workload in real-
life clinical routine.  
In this framework, deformable image registration allows the 
alignment of datasets in a non-linear way, providing a voxel-
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to-voxel mapping between the initial planning scan and the 
treatment scan. Therefore, deformation maps can be applied 
to propagate contours from planning CT to daily images, but 
also to compute dose distribution from the deformed images 
for dose accumulation purpose.  
In this presentation, we will describe the general framework 
of deformable image registration, and will cover the main 
class-solutions for registration-based recontouring according 
to the tumor location and the available imaging modality, 
i.e. kV- or MV/CB-CT. Typical adaptive workflows based on 
deformable registration will be presented, as well as their 
advantages and potential limitations. Last, we will emphasize 
the essential role of the operator for accuracy and 
consistency check of the deformed contours, any inaccuracy 
in this step necessarily introducing systematic errors in the 
planning process.  
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In the Erasmus MC radiotherapy department, atlas-based 
auto-segmentation of both clinical target volumes and organs 
at risk (OARs) is an important time-saving tool in daily clinical 
routine to assist both physicians and technicians. The 
accuracy of delineations has become increasingly important 
due to enhanced conformality of dose distributions as 
realized by IMRT and VMAT, and the use of reduced PTV 
margins in combination with image guidance. Clinical 
validation of atlas-based auto-segmentation for head-and-
neck patients showed a reduction of hands-on time for 
delineation from 180 to 66 minutes, where structures were 
evaluated as ‘minor-deviations, editable’ or better (D. Teguh 
; Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 4, pp. 
950–957, 2011). The influence of geometric differences 
between autocontours and manual delineations by different 
observers on the dosimetric impact can differ for CTV and for 
OAR (Voet PW, Radiother. Oncol. 2011 Mar;98(3):373-7). We 
clinically implemented Admire (Elekta AB, Sweden) as part of 
our workflow in 2010. In this workflow, critical review and 
editing of the autocontours is still relevant.  
For several target sites, a database was created containing 
fully contoured reference CT data sets (atlases). Depending 
on the tumor site, one or more atlases are used as an input 
for the generation of the patient-specific delineation (using 
the staple algorithm). The strategy of a single atlas can 
particularly be useful in case of adaptive treatments, 
resulting in a quick and more accurate autocontouring using 
the original delineated patient CT as the only atlas. An 
overview of the clinical implementation of Admire with 
regard to several tumor sites and the relation to treatment 
techniques such as breath-hold will be presented. 
 
Poster Viewing: 3: Clinical: Gastrointenstinal and 
gynaecology  
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Purpose or Objective: Preoperative level of CA 19-9 
(prCA19.9) predicts survival of patients (pts) undergoing 
surgery for pancreatic adenocarcinoma (PAC). Actually, there 
is no evidence of using prCA19.9 as a marker customizing and 
modulating effectiveness of adjuvant treatment or predicting 
pattern of failure. Therefore, the purpose of this pooled 
analysis was to determine whether prCA19.9 could predict 
overall survival (OS), local control (LC), disease metastasis 
free survival (DMFS) and evaluate effectiveness of adjuvant 
therapies in a broad population. 
 
Material and Methods: We performed a multicenter 
retrospective analysis of 1122 patients (pts) who underwent 
surgical resection +/- adjuvant treatment [chemotherapy 
(aCT), radiotherapy +/- concomitant CT (RCT)] for PAC 
between 2000 and 2014 from 8 different institutions. Among 
700 pts with prCA19.9 value we applied the Kaplan-Meier 
method and the log-rank test to investigate differences in 
OS, LC, DMFS between defined groups based on: clinical and 
pathological factors, 4 prCA19.9 cutoff (5, 37, 100, 353) and 
5 relative prCa19.9 classes (0.0-5.0, 5.1-37.0, 37.1-100, 
100.1-353.0, >353.1). We fitted Weibull regression model 
with shared frailty on institution to identify independent 
predictors of OS using data from 404 pts with complete 
information. We applied a backward stepwise strategy to 
select the covariates, forcing CRT and RT in the final model. 
 
Results: Median follow-up (FU) was 27 months (2-225). At 
univariate analysis there was a strong impact of prCA19.9 
classes (0.0-5.0, 5.1-37.0, 37.1-100, 100.1-353.0, >353.1) on 
5-years OS (5.7% vs 37.9 vs 27.1 vs 17.4 vs 10.9, p< 0.001, 
Figure 1), 5-years LC (47.2% vs 63.3% vs 59.4% vs 43.4% vs 
50.2%, p= 0.008), 5-years DMFS (17.0% vs 46.0% vs 39.0% vs 
26.7 vs 23.4, p<0.001), respectively. Only in pts with prCA 
19.9 > 353.1 U/ml aCT had positive impact on 5-year OS 
(47.4% in pts treated with aCT vs 30.2% in pts not treated 
with aCT, p= 0.006). At multivariable model, sub-analysis of 
404 pts showed (Table 1): worse OS for grading 3 tumor (HR: 
1.85 95%CI 1.26-2.70, p= 0.002) tumor diameter > 30 mm 
(HR: 1.85, 95%CI: 1.35-2.53, p< 0.001), and better OS for pts 
treated with RCT doses > 50 Gy (HR: 0.38, 95%CI: 0.23-0.63, 
p< 0.001). Median OS worsened in pts with prCA19.9 >100 and 
<353 (HR: 1.77, 95%CI: 1.23-2.56, p= 0.002) and in pts with 
prCA19.9 ≥353.1 (HR: 1.92, 95%CI: 1.34-2.76, p<0.001). 
 
